SynthesisCell proliferation2020
LncRNA SNHG15: A new budding star in human cancers.
Synthesis in Cell proliferation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic Accuracy of Exosomal Long Noncoding RNAs in Diagnosis of NSCLC: A Meta-Analysis.Molecular diagnosis & therapy · 2024Pooled it
- LncRNA SNHG15: A new budding star in human cancers.Cell proliferation · 2020Pooled it
- Identification of host lncRNAs that impact Venezuelan equine encephalitis virus TC-83 replication.Journal of virology · 2026Article
- The roles of the small nucleolar RNA host gene family in ovarian cancer.Cancer biology & therapy · 2025Review
- Manipulating PARK7/DJ-1 Levels by Genotoxic Stress Alters Noncoding RNAs and Cellular Homeostasis.Cells · 2025Article
- m5C-Modified lncRNA SNHG15 Promotes Ovarian Cancer Progression Via the miR-545-3p/PD-L1 Axis.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Integrative analysis of lncRNAs in rheumatoid arthritis: from bioinformatics to experimental validation.Clinical and experimental medicine · 2025Article
- LncRNA SNHG15 acts as a ceRNA to promote breast cancer progression through the miR-153-3p/KLF5 signal axis.Journal of Cancer · 2025Article
- The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer.Biomedicines · 2024Review
- Insights and implications for transcriptomic analysis of heat stress-induced intestinal inflammation in pigs.BMC genomics · 2024Article
- Small nucleolar RNAs and SNHGs in the intestinal mucosal barrier: Emerging insights and current roles.Journal of advanced research · 2023Review
- SNHG15 aids SARS-CoV-2 entry via RABL2A.RNA biology · 2023Article
- Long noncoding RNA SNHG15: A promising target in human cancers.Frontiers in oncology · 2023Review
- SOX9/MKLN1-AS Axis Induces Hepatocellular Carcinoma Proliferation and Epithelial-Mesenchymal Transition.Biochemical genetics · 2022Article
- Silencing the expression of lncRNAAnnals of translational medicine · 2022Article
- The Role of SNHG15 in the Pathogenesis of Hepatocellular Carcinoma.Journal of personalized medicine · 2022Review
- Long noncoding RNA SNHG17: a novel molecule in human cancers.Cancer cell international · 2022Review
- SNHG15 is a negative regulator of inflammation by mediating TRAF2 ubiquitination in stroke-induced immunosuppression.Journal of neuroinflammation · 2022Article
- SNHG15, a p53-regulated lncRNA, suppresses cisplatin-induced apoptosis and ROS accumulation through the miR-335-3p/ZNF32 axis.American journal of cancer research · 2022Article
- The clinical significance, immune infiltration, and tumor mutational burden of angiogenesis-associated lncRNAs in kidney renal clear cell carcinoma.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLong non-coding RNAs (lncRNAs) represent an important group of non-coding RNAs (ncRNAs) with more than 200 nucleotides in length that are transcribed from the so-called genomic "dark matter." Mounting evidence has shown that lncRNAs have manifested a paramount function in the pathophysiology of human diseases, especially in the pathogenesis and progression of cancers. Despite the exponential growth in lncRNA publications, our understanding of regulatory mechanism of lncRNAs is still limited, and a lot of controversies remain in the current lncRNA knowledge.The purpose of this article is to explore the clinical significance and molecular mechanism of SNHG15 in tumors. MATERIALS &
methodsWe have systematically searched the Pubmed, Web of Science, Embase and Cochrane databases. We provide an overview of current evidence concerning the functional role, mechanistic models and clinical utilities of SNHG15 in human cancers in this review.
resultsSmall nucleolar RNA host gene 15 (SNHG15), a novel lncRNA, is identified as a key regulator in tumorigenesis and progression of various human cancers, including colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PC) and hepatocellular carcinoma (HCC). Dysregulation of SNHG15 has been revealed to be dramatically correlated with advanced clinicopathological factors and predicts poor prognosis, suggesting its potential clinical value as a promising biomarker and therapeutic target for cancer patients.
conclusionsLncRNA SNHG15 may serve as a prospective and novel biomarker for molecular diagnosis and therapeutics in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.